A Test to Predict the Hemolytic Potential of Drugs in G6PD Deficiency

Overview

This study will evaluate a new and safe testing method for identifying medicines that can cause problems in glucose-6-phosphate dehydrogenase (G6PD) deficient individuals. We are looking for volunteers with G6PD deficiency who would be willing to donate blood samples.

Full Title of Study: “A New Test to Predict the Hemolytic Potential of Drugs in G6PD Deficiency”

Study Type

• Study Type: Interventional
• Study Design
  • Allocation: Non-Randomized
  • Intervention Model: Single Group Assignment
  • Primary Purpose: Prevention
  • Masking: None (Open Label)

Interventions

• Drug: Primaquine

Clinical Trial Outcome Measures

Primary Measures

• Difference in degree of hemolysis of G6PD(-) red blood cells in treated vs untreated matched samples.

Participating in This Clinical Trial

Inclusion:

• Normal clinical evaluation – Willing and able to make all scheduled visits Exclusion: – pregnant or planning pregnancy – Have taken any anti-malarial medication in past month – Positive blood tests for HIV and specific types of hepatitis – Allergic to primaquine

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 60 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

• Lead Sponsor
  • Walter Reed Army Institute of Research (WRAIR)
• Overall Official(s)
  • Shon A Remich, Principal Investigator, WRAIR, Experimental Therapeutics